Tolcapone
Talk0this wiki
Assessment |
Biopsychology |
Comparative |
Cognitive |
Developmental |
Language |
Individual differences |
Personality |
Philosophy |
Social |
Methods |
Statistics |
Clinical |
Educational |
Industrial |
Professional items |
World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology
|
Tolcapone chemical structure | |
| 2-dihydroxyamino-4- (4-methylbenzoyl)- cyclohexa-2,4-diene-1,6-dione IUPAC name | |
| CAS number 134308-13-7 | ATC code |
| PubChem 4659569 | DrugBank APRD00445 |
| Chemical formula | {{{chemical_formula}}} |
| Molecular weight | 273.241 g/mol |
| Bioavailability | 65% |
| Metabolism | |
| Elimination half-life | 2-3.5 hours |
| Excretion | {{{excretion}}} |
| Pregnancy category | {{{pregnancy_category}}} |
| Legal status | {{{legal_status}}} |
| Routes of administration | Oral |
Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound with a relative molecular mass of 273.25. The chemical name of tolcapone is 3,4-dihydroxy-4’-methyl-5-nitrobenzophenone. Its empirical formula is C14H11NO5.
Tolcapone has the ability to cross the blood-brain barrier and thus exerts its COMT inhibitory effects in the CNS as well as in the periphery.
Tolcapone has demonstrated significant hepatotoxicity that limits the drug's therapeutic utility to a drug of last resort. Entacapone, another COMT inhibitor, is a more popular selection for L-DOPA adjunct therapy in the treatment of Parkinson's Disease because it has a better side effect and toxicity profile.
Normally, administration of levodopa is compromised when COMT converts it to methyldopa. By preventing this effect, more of the levodopa that is administered reaches the CNS. Additionally, levodopa that is in the CNS, after being converted to dopamine, will not be degraded by COMT when tolcapone inhibits COMT activity.
Anti-parkinson drugs: dopaminergic agents (N04B) | |
|---|---|
| Dopa and derivatives | |
| Adamantane derivatives | |
| Dopamine agonists |
Apomorphine, Bromocriptine, Cabergoline, Dihydrexidine, Dihydroergocryptine mesylate, Fenoldopam, Lisuride, Pergolide, Piribedil, Pramipexole, Quinpirole, Ropinirole, Rotigotine, SKF 38393, SKF 82958 |
| MAOIs | |
| Other |
Tolcapone, Entacapone, Budipine |
| This page uses Creative Commons Licensed content from Wikipedia (view authors). |
